Department of Basic Biotechnological Sciences, Intensive and Perioperative Clinics, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
Department of Laboratory and Infectious Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168, Rome, Italy.
Sci Rep. 2024 Feb 9;14(1):3344. doi: 10.1038/s41598-024-51480-2.
Endoscopic Retrograde Cholangio-Pancreatography (ERCP) with biliary stenting is a minimally invasive medical procedure employed to address both malignant and benign obstructions within the biliary tract. Benign biliary strictures (BBSs), typically arising from surgical interventions such as liver transplants and cholecystectomy, as well as chronic inflammatory conditions, present a common clinical challenge. The current gold standard for treating BBSs involves the periodic insertion of plastic stents at intervals of 3-4 months, spanning a course of approximately one year. Unfortunately, stent occlusion emerges as a prevalent issue within this treatment paradigm, leading to the recurrence of symptoms and necessitating repeated ERCPs. In response to this clinical concern, we initiated a pilot study, delving into the microbial composition present in bile and on the inner surfaces of plastic stents. This investigation encompassed 22 patients afflicted by BBSs who had previously undergone ERCP with plastic stent placement. Our preliminary findings offered promising insights into the microbial culprits behind stent occlusion, with Enterobacter and Lactobacillus spp. standing out as prominent bacterial species known for their biofilm-forming tendencies on stent surfaces. These revelations hold promise for potential interventions, including targeted antimicrobial therapies aimed at curtailing bacterial growth on stents and the development of advanced stent materials boasting anti-biofilm properties.
经内镜逆行胰胆管造影术(ERCP)联合胆道支架置入术是一种微创医疗程序,用于解决胆道内的恶性和良性阻塞。良性胆道狭窄(BBS)通常由肝移植和胆囊切除术等外科干预以及慢性炎症引起,是一个常见的临床挑战。目前治疗 BBS 的金标准是每隔 3-4 个月周期性地插入塑料支架,持续大约一年的时间。不幸的是,支架阻塞成为这种治疗方案中的一个普遍问题,导致症状复发,并需要反复进行 ERCP。针对这一临床关注,我们开展了一项试点研究,深入研究胆汁和塑料支架内表面的微生物组成。该研究纳入了 22 名曾接受过 ERCP 联合塑料支架置入术治疗的 BBS 患者。我们的初步研究结果为支架阻塞背后的微生物罪魁祸首提供了有希望的见解,肠杆菌和乳杆菌属等细菌是在支架表面形成生物膜的著名细菌种类。这些发现为潜在的干预措施提供了希望,包括针对支架上细菌生长的靶向抗菌治疗以及开发具有抗生物膜特性的先进支架材料。